Sesamin, derived from sesame seeds, is known to have various biological eŠects. Since some of these eŠects appear to be derived from its metabolites, the elucidation of sesamin metabolism is essential to understanding the molecular mechanism of its eŠects. In addition, it is important to clarify drug-sesamin interactions in order to address safety concerns, as some food factors are known to aŠect drug metabolism. Our previous studies revealed that sesamin was sequentially metabolized by cytochrome P450 (CYP) and UDP-glucuronosyltransferase or sulfotransferase. Whereas sesamin metabolism is mainly mediated by CYP2C9 in human liver, sesamin causes a mechanism-based inhibition (MBI) of CYP2C9. However, we found that the metabolite-intermediate complex between CYP2C9 and sesamin was unstable, and the eŠects of sesamin appeared to be minimal. To conˆrm this assumption, in vivo studies using rats were conducted. After the administration of sesamin to rats for 3 d, diclofenac (an NSAID) was administered to measure the time course of plasma concentration of diclofenac. No signiˆcant diŠerences were observed in the diclofenac C max , T max , and AUC 0 24 h between the group that was administered sesamin and the group that was not. Based on these results, it could be concluded that no signiˆcant interaction occurs in people who take sesamin supplements at a standard dose. 
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